

January 1631 P

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Michael J. Amdahl

Serial No.: 09/975,853

Filed: October 12, 2001

Title: A METHOD OF
DETERMINING THE INITIAL DOSE
OF VITAMIN D COMPOUNDS

Case No.: 6741.US.01

Group Art No.: 1631

Examiner: Cheyne D. Ly

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: October 29, 2003

Robin S. Evans 10/29/03
Robin S. Evans Date

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith for the patent application identified above entitled A METHOD OF DETERMINING THE INITIAL DOSE OF VITAMIN D COMPOUNDS are the following:

1. Information Disclosure Statement
2. Form PTO-1449, in duplicate
3. Copy of References as cited on Form PTO-1449 (5 Total);
4. Copy of International Search Report; and
5. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR § 1.16, as well as any patent application processing fees under 37 CFR § 1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.



23492

ABBOTT LABORATORIES
Telephone: (847) 937-4558
Facsimile: (847) 938-2623

Respectfully submitted,
Michael J. Amdahl

Patricia Coleman James
Patricia R. Coleman James
Registration No. 37,155
Attorney for Applicants



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Michael J. Amdahl

Serial No.: 09/975,853

Filed: October 12, 2001

Title: A METHOD OF DETERMINING
THE INITITAL DOSE OF
VITAMIN D COMPOUNDS

Case No.: 6741.US.01


Group Art Unit: 1631

Examiner: Cheyne D. Ly

I hereby certify that this paper
(along with any paper referred
to as being attached or enclosed)
is being deposited with the United
States Postal Service as First
Class Mail on the date shown below
with sufficient in an envelope
addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: October 29, 2003

 10-29-03
Robin S. Evans Date

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in 37 C.F.R. §1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final Action or a Notice of Allowance, and is accompanied by the Petition fee of \$180.00 as specified under 37 C.F.R. §1.97(c). Applicant respectfully petitions and requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

11/04/2003 YPOLITE1 00000086 010025 09975053

01 FC:1806 180.00 DA

Each document listed in this Information Disclosure Statement was first cited by a foreign patent office in a communication from the European Patent office in a counterpart international PCT application.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Applicants hereby authorize the Commissioner to charge the appropriate Petition fee of \$180.00 to Deposit Account No. 01-0025. The Commissioner also is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered. A duplicate of this sheet is enclosed.




* 2 3 4 9 2 *

23492

ABBOTT LABORATORIES
Telephone: (847) 937-4558
Facsimile: (847) 938-2623

Respectfully submitted,
Michael J. Amdahl



Patricia R. Coleman James
Registration No. 37,155
Attorney for Applicants



DATE: October 29, 2003

SHEET 1 of 1

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.	SERIAL NO.
		6741.US.01	09/975,853
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT(S)	
(Use several sheets if necessary)		Michael J. Amdahl	
		FILING DATE	GROUP
		October 12, 2001	1631

U.S. PATENT DOCUMENTS

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	C1	K. J. Martin et al, "Therapy of Secondary Hyperparathyroidism with 19-Nor-1a, 25-Dihydroxyvitamin D ₂ ", American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, vol. 32, no. 2, Suppl 2, October 1998, pp. S61-S66.
	C2	D. J. Cada et al, "Paricalcitol Injection and Ribavirin/Interferon Alfa-2b", Hospital Pharmacy, vol. 34, no. 3, 1999, pp. 303-338.
	C3	F. Llach et al, "The Importance of Dosing Intravenous Calcitriol in Dialysis Patients with Severe Hyperthyroidism", American Journal of Kidney Diseases: The Official Journal of National Kidney Foundation, vol. 26, no. 5, November 1995, pp. 845-851
	C4	S. M. Sprague et al, "Safety and Efficacy of Long-Term Treatment of Secondary Hyperparathyroidism by Low-Dose Intravenous Calcitriol", American Journal of Kidney Diseases: The Official Journal of National Kidney Foundation, vol. 19, no. 6, June 1992, pp. 532-539
	C5	K. J. Martin et al, "Paricalcitol Dosing According to Body Weight or Severity of Hyperparathyroidism: a Double-Blind, Multicenter, Randomized Study", American Journal of Kidney Diseases: The Official Journal of National Kidney Foundation, vol. 38, no. 5, Suppl 5, November 2001, pp. S57-S63

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)